NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NGNE NEUROGENE INC

Post-Mkt 01-20 18:53:42 EST

17.52

-0.03

-0.17%

盘后17.17

-0.35-2.00%

18:45 EST

High17.89	Low16.94	Vol78.53K
Open17.11	D1 Closing17.55	Amplitude5.46%
Mkt Cap271.38M	Tradable Cap105.43M	Total Shares15.49M
T/O1.37M	T/O Rate1.30%	Tradable Shares6.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NGNE","market":"US","secType":"STK","nameCN":"NEUROGENE INC","latestPrice":17.52,"timestamp":1768942800000,"preClose":17.55,"halted":0,"volume":78528,"hourTrading":{"tag":"盘后","latestPrice":17.17,"preClose":17.52,"latestTime":"18:45 EST","volume":1994,"amount":34933.831156,"timestamp":1768952733914,"change":-0.35,"changeRate":-0.019977,"amplitude":0.019977},"delay":0,"changeRate":-0.001709401709401774,"floatShares":6017500,"shares":15489800,"eps":-4.120047,"marketStatus":"Post-Mkt","change":-0.03,"latestTime":"01-20 18:53:42 EST","open":17.11,"high":17.8934,"low":16.935,"amount":1372620.9096960002,"amplitude":0.05461,"askPrice":20.98,"askSize":100,"bidPrice":16.9,"bidSize":30,"shortable":3,"etf":0,"ttmEps":-4.120047,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1768957200000},"marketStatusCode":4,"adr":0,"listingDate":1394168400000,"exchange":"NASDAQ","adjPreClose":17.55,"postHourTrading":{"tag":"盘后","latestPrice":17.17,"preClose":17.52,"latestTime":"18:45 EST","volume":1994,"amount":34933.831156,"timestamp":1768952733914,"change":-0.35,"changeRate":-0.019977,"amplitude":0.019977},"volumeRatio":0.52054,"impliedVol":0.9926,"impliedVolPercentile":0.2629},"requestUrl":"/m/hq/s/NGNE/tweets","defaultTab":"tweets","newsList":[{"id":"2603068911","title":"Neurogene Price Target Maintained With a $70.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2603068911","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603068911?lang=en_us&edition=fundamental","pubTime":"2026-01-13 20:31","pubTimestamp":1768307460,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 07:31 ET (12:31 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2603853936","title":"Neurogene (NGNE) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2603853936","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603853936?lang=en_us&edition=fundamental","pubTime":"2026-01-13 19:36","pubTimestamp":1768304212,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Neurogene today and set a price target of $70.00. According to TipRanks, Kapoor ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neurogene-ngne-gets-a-buy-from-h-c-wainwright-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neurogene-ngne-gets-a-buy-from-h-c-wainwright-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2603863542","title":"Neurogene Showcases Rett Syndrome Gene Therapy Progress at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2603863542","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603863542?lang=en_us&edition=fundamental","pubTime":"2026-01-13 00:27","pubTimestamp":1768235271,"startTime":"0","endTime":"0","summary":"Neurogene Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14 at 7:30 a.m. PT. The presentation will be accessible via webcast from the Investor Relations section of Neurogene's website, with a replay available for a limited time.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 12, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL3VldlY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2602514911","title":"Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome with Embolden Trial Dosing and Upcoming 2026 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2602514911","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602514911?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:01","pubTimestamp":1768219298,"startTime":"0","endTime":"0","summary":"Neurogene Inc. announced recent progress in its NGN-401 gene therapy program for Rett syndrome. Multiple participants have been dosed in the Embolden registrational trial, with dosing expected to be completed in the second quarter of 2026. The company plans to present interim safety and efficacy data from its Phase 1/2 trial, including at least 12 months of follow-up for all participants in the pediatric and adolescent/adult cohorts, in mid-2026. Early commercial-readiness activities are underway, and Neurogene has reported positive interim data from the Phase 1/2 trial, demonstrating durable multidomain improvements across a spectrum of disease severity. The company is scheduled to present at the J.P. Morgan Healthcare Conference on January 14.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL343X1y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0034235303.USD","LU0689472784.USD","IE00B775SV38.USD","LU0320765646.SGD","LU0345770993.USD","LU0820561909.HKD","LU2756315318.SGD","LU2381873111.SGD","IE00BJTD4N35.SGD","LU0251132253.USD","LU2242649171.HKD","IE0034235295.USD","LU2505996509.AUD","LU2417539215.USD","LU0106261372.USD","LU0267386448.USD","LU1974910355.USD","LU0310799852.SGD","LU0048584097.USD","LU0215105999.USD","LU2237443895.HKD","NGNE","BK4534","LU0208291251.USD","LU2237443549.SGD","IE00BWXC8680.SGD","LU1720051017.SGD","LU0868494708.USD","LU2430703095.HKD","LU1551013342.USD","LU1551013425.SGD","LU0345769631.USD","IE00BLSP4452.SGD","LU2237443622.USD","LU1032466523.USD","LU2211815571.USD","IE00BJLML261.HKD","LU2430703251.USD","LU1261432733.SGD","LU2213496289.HKD","LU2023250330.USD","LU0149725797.USD","LU1496350502.SGD","IE00BHPRN162.USD","BK4566","LU0868494617.USD","LU2746668974.SGD","IE00BKDWB100.SGD","IE00BJTD4V19.USD","LU2054465674.USD"],"gpt_icon":0},{"id":"2602594514","title":"Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for Ngn-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2602594514","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602594514?lang=en_us&edition=fundamental","pubTime":"2026-01-12 20:00","pubTimestamp":1768219202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUASZXTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2601860768","title":"Neurogene Inc. to Present Company Overview at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2601860768","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601860768?lang=en_us&edition=fundamental","pubTime":"2026-01-05 20:30","pubTimestamp":1767616224,"startTime":"0","endTime":"0","summary":"Neurogene Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference, where company management will present a company overview and engage in investor meetings on Wednesday, January 14 at 7:30 a.m. PT. A webcast of the presentation will be available on Neurogene's Investor Relations website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on January 05, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260105:nNDL34tMDH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2589832071","title":"Neurogene Grants Stock Options to New Employees Under 2025 Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2589832071","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589832071?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:01","pubTimestamp":1764882071,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has approved the grant of non-qualified stock options to purchase a total of 4,860 shares of the company's common stock for two new employees. These options have an exercise price equal to the closing price of Neurogene's shares on the grant date and will vest over four years: 25 percent will vest on the first anniversary of the vesting commencement date, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this news brief via Business Wire  on December 04, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDLzWXSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2589061832","title":"Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2589061832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589061832?lang=en_us&edition=fundamental","pubTime":"2025-12-05 05:01","pubTimestamp":1764882060,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nTUA7JF56M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2584922459","title":"Neurogene Q3 EPS USD -0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2584922459","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584922459?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:42","pubTimestamp":1763574122,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - Neurogene Q3 net income USD -20.953 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 13-NOV-202522:10:45.873 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSDc9whDZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583100985","title":"Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2583100985","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583100985?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:26","pubTimestamp":1763072779,"startTime":"0","endTime":"0","summary":"Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48853048/neurogene-q3-eps-0-99-beats-1-25-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neurogene Q3 EPS $(0.99) Beats $(1.25) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583783510","title":"Gene therapy developer Neurogene's Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2583783510","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583783510?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:20","pubTimestamp":1763072409,"startTime":"0","endTime":"0","summary":"Gene therapy developer Neurogene's Q3 net loss widensOverviewCompany maintains strong cash position, funding operations through Q1 2028Net loss for Q3 2025 was $21.0 mln, slightly higher than Q3 2024O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP1D1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583510676","title":"BRIEF-Neurogene Q3 EPS USD -0.99","url":"https://stock-news.laohu8.com/highlight/detail?id=2583510676","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583510676?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071845,"startTime":"0","endTime":"0","summary":"BRIEF-Neurogene Q3 EPS USD -0.99\n\n\nNov 13 (Reuters) - Neurogene Q3 net income USD -20.953 million.\n\nQ3 operating expenses USD 23.798 million\nQ3 operating income USD -23.798 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX0792C3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583851098","title":"Neurogene reports positive interim data from NGN-401 Phase 1/2 trial for Rett syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2583851098","media":"Reuters","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583851098?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071825,"startTime":"0","endTime":"0","summary":"Neurogene Inc. reported a net loss of $21.0 million for the third quarter ended September 30, 2025, compared to a net loss of $20.2 million for the same period in 2024. Cash, cash equivalents, and short-term investments totaled $265.4 million as of September 30, 2025. The company expects its current cash position to fund planned operations through the first quarter of 2028. During the period, Neurogene announced positive interim data from the NGN-401 Phase 1/2 gene therapy trial for Rett syndrome and began dosing participants in the Embolden registrational trial, with full enrollment anticipated within three to six months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurogene Inc. published the original content used to generate this","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL38m9Qn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583606510","title":"Neurogene Q3 Operating Income USD -23.798 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583606510","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583606510?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nPLX0792C3:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583106035","title":"Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2583106035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583106035?lang=en_us&edition=fundamental","pubTime":"2025-11-14 06:10","pubTimestamp":1763071800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA3CY09T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","NGNE"],"gpt_icon":0},{"id":"2583956795","title":"Stifel Nicolaus Remains a Buy on Neurogene (NGNE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2583956795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583956795?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:56","pubTimestamp":1763042186,"startTime":"0","endTime":"0","summary":"In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Neurogene, with a price target of $46.00. Matteis covers t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-neurogene-ngne-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-remains-a-buy-on-neurogene-ngne-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","BK4139","SF","NGNE"],"gpt_icon":0},{"id":"2583609145","title":"Neurogene Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2583609145","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583609145?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:54","pubTimestamp":1763038440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NGNE/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 13, 2025 07:54 ET (12:54 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583300453","title":"Neurogene Reports Positive Interim Results for NGN-401 Gene Therapy in Pediatric Rett Syndrome Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2583300453","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583300453?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981319,"startTime":"0","endTime":"0","summary":"Neurogene Inc. has announced updated interim clinical data from its ongoing Phase 1/2 trial evaluating NGN-401 gene therapy for the treatment of females with Rett syndrome. The data, drawn from the pediatric cohort , indicate that all eight participants experienced functional gains and acquired a total of 35 developmental milestones or skills across varying levels of disease severity. The reported improvements have shown durability, with continued skill acquisition observed over time and sustained gains up to 24 months post-treatment. NGN-401 at the registrational dose has been generally well-tolerated, with no evidence of HLH. Neurogene management will discuss these results and the Embolden registrational trial at the Stifel 2025 Healthcare Conference. The webcast presentation is scheduled for today at 4:40 p.m. ET, with a replay to be available on the company's website. Additional clinical data are expected to be reported in 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL3MprZ7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583585537","title":"Neurogene Inc - Ngn-401 Well-Tolerated With No Evidence of Hlh","url":"https://stock-news.laohu8.com/highlight/detail?id=2583585537","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583585537?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9YSFBX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0},{"id":"2583300131","title":"Neurogene Reports Positive Interim Data in Pediatric Cohort From Ngn-401 Gene Therapy Trial for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2583300131","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583300131?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:01","pubTimestamp":1762981260,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nTUA9YSFBX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGNE","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurogene.com","stockEarnings":[{"period":"1week","weight":-0.0206},{"period":"1month","weight":-0.0831},{"period":"3month","weight":-0.3955},{"period":"6month","weight":-0.2144},{"period":"1year","weight":-0.0045},{"period":"ytd","weight":-0.1481}],"compareEarnings":[{"period":"1week","weight":-0.0035},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.041},{"period":"6month","weight":0.1021},{"period":"1year","weight":0.1691},{"period":"ytd","weight":0.0143}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.035135},{"month":2,"riseRate":0.363636,"avgChangeRate":-0.050266},{"month":3,"riseRate":0.454545,"avgChangeRate":0.037124},{"month":4,"riseRate":0.25,"avgChangeRate":-0.076909},{"month":5,"riseRate":0.5,"avgChangeRate":0.000899},{"month":6,"riseRate":0.416667,"avgChangeRate":-0.072235},{"month":7,"riseRate":0.5,"avgChangeRate":-0.055031},{"month":8,"riseRate":0.833333,"avgChangeRate":0.776521},{"month":9,"riseRate":0.25,"avgChangeRate":-0.065331},{"month":10,"riseRate":0.416667,"avgChangeRate":0.020322},{"month":11,"riseRate":0.416667,"avgChangeRate":0.000025},{"month":12,"riseRate":0.583333,"avgChangeRate":0.147487}],"exchange":"NASDAQ","name":"NEUROGENE INC","nameEN":"NEUROGENE INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NEUROGENE INC,NGNE,NEUROGENE INC股票,NEUROGENE INC股票老虎,NEUROGENE INC股票老虎国际,NEUROGENE INC行情,NEUROGENE INC股票行情,NEUROGENE INC股价,NEUROGENE INC股市,NEUROGENE INC股票价格,NEUROGENE INC股票交易,NEUROGENE INC股票购买,NEUROGENE INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEUROGENE INC(NGNE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NEUROGENE INC(NGNE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}